BibTex RIS Cite

Low-Grade Endometrial Stromal Sarcoma Following Tamoxifen Treatment

Year 2016, Özel Sayı, 9 - 10, 01.06.2016

Abstract

Tamoxifen TMX is supposed to be related with development of uterine sarcomas. Due to the low incidence of uterine sarcomas, establishment of a causal relationship with TMX is difficult. These sarcomas mostly appear 5 or 8 years after TMX administration and tend to display an aggressive behaviour. In this report, we present a rare case of endometrial stromal sarcoma detected in a breast cancer patient who had been treated with TMX for only two years. Up to now, nearly 65 endometrial stromal sarcoma cases have been reported after TMX treatment in the literature, and a meticulous follow-up is important in patients that will receive TMX therapy.

References

  • Chan JK, Kawar NM, Shin JY, Osann K, Chen LM, Powell CB, Kapp DS. Endometrial stromal sarcoma: a population-based analysis. Br J Cancer 2008; 99: 1210-1215.
  • Wickerham DL, Fisher B, Wolmark N, Bryant J, Costantino J, Bernstein L, Runowicz CD. Association of tamoxifen and uterine sarcoma. J Clin Oncol 2002; 20: 2758–2760.
  • Brooks SE, Zhan M, Cote T, Baquet CR. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999. Gy- necol Oncol 2004; 93: 204-208.
  • Ihnen M, Mahner S, Jänicke F, Schwarz J. Current treatment options in uterine endometrial stromal sarcoma: report of a case and review of the literature. Int J Gynecol Cancer 2007; 17: 957-963.
  • American College of Obstetricians and Gynecologists Committee on Gy- necologic Practice. ACOG committee opinion. No. 336: Tamoxifen and uterine cancer. Obstet Gynecol 2006; 107: 1475-1478.

Tamoksifen Tedavisini Takiben Gelişen Düşük Gradeli Endometriyal Stromal Sarkom

Year 2016, Özel Sayı, 9 - 10, 01.06.2016

Abstract

Tamoksifen TMX kullanımının, uterin sarkom gelişimi ile ilişkili olduğu düşünülmektedir. Uterin sarkomların görülme insidansının düşük olması nedeniyle TMX kullanımına bağlı nedensel bir ilişki kurmak zordur. Bu sarkomlar çoğunlukla TMX tedavisi başladıktan 5 ile 8 yıl sonrasında ortaya çıkarlar ve daha agresif bir davranış sergileme eğilimindedirler. Bu yazıda, sadece iki yıl TMX tedavisi almış meme kanseri olan hastada tespit edilen endometriyal stromal sarkom olgusunu sunduk. Literatürde şimdiye kadar yaklaşık 65 TMX kullanımı sonrası gelişen uterin sarkom vakası rapor edilmiştir. TMX tedavisi alan meme kanseri hastalarında jinekolojik titiz takip esastır.

References

  • Chan JK, Kawar NM, Shin JY, Osann K, Chen LM, Powell CB, Kapp DS. Endometrial stromal sarcoma: a population-based analysis. Br J Cancer 2008; 99: 1210-1215.
  • Wickerham DL, Fisher B, Wolmark N, Bryant J, Costantino J, Bernstein L, Runowicz CD. Association of tamoxifen and uterine sarcoma. J Clin Oncol 2002; 20: 2758–2760.
  • Brooks SE, Zhan M, Cote T, Baquet CR. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999. Gy- necol Oncol 2004; 93: 204-208.
  • Ihnen M, Mahner S, Jänicke F, Schwarz J. Current treatment options in uterine endometrial stromal sarcoma: report of a case and review of the literature. Int J Gynecol Cancer 2007; 17: 957-963.
  • American College of Obstetricians and Gynecologists Committee on Gy- necologic Practice. ACOG committee opinion. No. 336: Tamoxifen and uterine cancer. Obstet Gynecol 2006; 107: 1475-1478.
There are 5 citations in total.

Details

Primary Language Turkish
Journal Section Case Report
Authors

Ülkü Mete Ural This is me

Recep Bedir This is me

Publication Date June 1, 2016
Published in Issue Year 2016 Özel Sayı

Cite

Vancouver Ural ÜM, Bedir R. Tamoksifen Tedavisini Takiben Gelişen Düşük Gradeli Endometriyal Stromal Sarkom. JGON. 2016;13:9-10.